The GPNMB Knockout KYSE-30 Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population in which the GPNMB gene has been disrupted. This heterogeneous population provides a loss-of-function model for investigating the role of GPNMB in esophageal squamous cell carcinoma biology. The knockout pool is derived from the KYSE-30 cell line and is suitable for functional genomic experiments, target validation, and drug response profiling.
The KYSE-30 host cell line is a well-differentiated human esophageal squamous cell carcinoma line originating from a resected tumor of a male patient. These cells retain key characteristics of invasive squamous cell carcinoma and are widely used as a model system to study oncogenic signaling, tumor cell motility, and therapeutic sensitivities in esophageal cancers.
GPNMB encodes a type I transmembrane glycoprotein that functions as a cell surface receptor mediating cell?Cmatrix interactions. Upon binding to integrin receptors such as ITGB1 and ITGA5, GPNMB triggers intracellular signal transduction through the PI3K/AKT and ERK/MAPK pathways. This engagement activates downstream effectors including FAK, SRC, AKT1, MAPK1, and MAPK3, while upstream regulators such as MITF, TGFB1, and EGF modulate GPNMB expression. Additionally, GPNMB interacts with CD44 and HSPG2, integrating adhesive and migratory cues that drive tumor progression.
In KYSE-30 cells, GPNMB is linked to enhanced cell migration and invasion, processes fundamental to squamous cell carcinoma invasiveness. The knockout of GPNMB in this cellular context is expected to impair PI3K/AKT and ERK/MAPK signaling, leading to reduced cell motility and survival. This engineered cell population thus represents a valuable tool for dissecting the molecular underpinnings of esophageal cancer progression and for evaluating the dependency of these malignant traits on GPNMB-mediated signaling.
Researchers can employ this polyclonal knockout cell model in a variety of functional assays, including Western blotting and RT-qPCR to confirm GPNMB loss, transwell migration and invasion assays to assess motility changes, and phospho-AKT and phospho-ERK analyses to interrogate pathway activity. The population is also suitable for RNA-seq transcriptomic profiling and drug sensitivity screens to identify GPNMB-dependent therapeutic vulnerabilities. For further technical details and ordering information, please contact Ascent Research.
